 Becton Dickinson and Co. said Wednesday that the U.S. government plans to buy 750,000 of the companys COVID-19 antigen diagnostic tests. The purchase will also include 2,000 systems manufactured by BD to run the tests. BD was granted an emergency use authorization from the Food and Drug Administration for the rapid, point-of-care test earlier this month, making it the third of its diagnostics tests to receive emergency authorization. The regulator, also in July,issued an alert about the risk of false-positive results for another one of BDs diagnostic coronavirus tests. BDs stock is down 3.1 year-to-date, while the SP; 500 has declined 1.0. 